Empowering Through Excellence

Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology,  inflammation, and rare/specialty diseases.

With direct access to world-class, expedited and end-to-end technologies in the antibody discovery and development process, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships. For further information contact bd@talemtherapeutics.com.

About Us

Empowering Teams, Transforming Therapeutics

Talem Therapeutics (Talem) is a wholly owned subsidiary of ImmunoPrecise Antibodies (IPA) and is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies to target multiple disease indications.

Using the proprietary antibody discovery platforms and innovative technologies housed at ImmunoPrecise Antibodies, Talem aims to accelerate novel, high-value, therapeutic antibody treatments to the clinic.

Transgenic
Animals at Talem

We have optimized our powerful, custom, species-agnostic technologies for use with transgenic animal platforms to enable the discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy as well as the lowest immunogenicity. The ability to select very specific, “needle-in-a-haystack” human antibodies via this advanced combination offers an entirely new avenue of therapeutic antibody discovery. Talem is the only CRO affiliate globally to offer these services as a partnership with OmniAb® transgenic (www.omniab.com) animals using their own license.

The PolyTope® Advantage

Talem has been actively involved in SARS-CoV-2 research since January 2020. One of its most advanced development programs, TATX-03 (anti-SARS-CoV-2 PolyTope® antibody cocktail), is a rationally designed, fully human, 4-antibody cocktail containing potently neutralizing antibodies against non-overlapping epitopes on SARS-CoV-2. Talem’s SARS-CoV-2 PolyTope® therapy is designed to reduce mutagenic escape risk with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2, and has been developed with the goal of sustainable efficacy as the virus evolves, combining broadly characterized, neutralizing and synergistic antibodies that exhibit diverse epitope coverage.

> Polytope® TATX-03 Additional Information

Partner with Talem

Talem Therapeutics is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeted toward any disease indication.

With direct access to world-class, expedited and end-to-end technologies in antibody discovery, characterization, manufacturing and engineering, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships.

News

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
March 29th, 2022

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense
March 14th, 2022

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
January 31, 2022

ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
December 20th, 2021

ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
November 30th, 2021

Contact Us

For Business Development or Partnering Opportunities
bd@talemtherapeutics.com
One Broadway, 14th floor
Cambridge, MA 02142, USA

For Investor Inquiries
Frédéric Chabot
investors@immunoprecise.com

ImmunoPrecise Antibodies
Immunoprecise.com